serolog
respons
profil
sever
acut
respiratori
syndrom
sar
coronaviru
cov
infect
defin
neutral
test
subclassspecif
immunofluoresc
test
use
serial
sera
patient
sar
cov
total
immunoglobulin
ig
igg
iga
igm
iggam
first
antibodi
detect
differ
time
seroconvers
patient
surviv
n
die
n
although
sar
cov
igm
still
detect
test
patient
month
postinfect
geometr
mean
titer
drop
month
postinfect
month
p
contrast
neutral
antibodi
sar
cov
iggam
igg
antibodi
titer
remain
stabl
period
sar
cov
antibodi
respons
sometim
associ
increas
preexist
igg
antibodi
titer
human
coronavirus
chang
igg
titer
viru
capsid
antigen
herpesviru
use
unrel
control
epsteinbarr
viru
contrast
patient
infect
probabl
also
infect
without
prior
exposur
sar
cov
increas
antibodi
specif
infect
viru
sar
cov
need
awar
crossreact
antibodi
respons
coronavirus
interpret
serolog
sever
acut
respiratori
syndrom
sar
newli
emerg
infecti
diseas
pose
major
threat
intern
public
health
novel
coronaviru
cov
identifi
etiolog
agent
sar
cov
serolog
indirect
immunofluoresc
neutral
test
regard
gold
standard
diagnosi
sar
coronaviru
infect
two
previou
studi
immunoglobulin
g
igg
seroconvers
sar
cov
occur
mean
day
day
onset
symptom
followup
serum
sampl
patient
collect
day
onset
symptom
demonstr
persist
high
igg
antibodi
titer
anoth
studi
igm
antibodi
found
becom
undetect
approxim
week
onset
ill
howev
full
serolog
profil
remain
larg
undefin
human
coronavirus
long
known
respiratori
pathogen
human
recent
discov
two
novel
coronavirus
infect
human
virus
group
coronavirus
classifi
group
virus
taxonom
classif
sar
cov
still
debat
though
mani
argu
distant
rel
group
coronavirus
previou
studi
reveal
signific
evid
sar
cov
antibodi
uninfect
healthi
control
although
individu
would
expect
antibodi
common
human
coronavirus
therefor
assum
posit
sar
cov
result
taken
unequivoc
evid
sar
cov
infect
conflict
opinion
concern
serolog
crossreact
human
coronavirus
remain
enzymelink
immunosorb
assay
elisa
use
human
antibodi
respons
clearli
distinguish
howev
crossreact
respons
detect
complement
fixat
test
elisa
use
recombin
viral
protein
sinc
addit
human
coronavirus
discov
view
global
public
health
import
diagnos
sar
remain
import
revisit
question
potenti
crossreact
human
serolog
respons
coronavirus
present
studi
serial
sera
sar
patient
collect
ill
convalesc
month
postinfect
test
neutral
test
nt
test
sar
covspecif
igg
iga
igm
total
antibodi
igg
iga
igm
iggam
sera
patient
sar
test
crossreact
human
coronavirus
test
sinc
still
cultur
vitro
viru
includ
serolog
studi
report
furthermor
acuteand
convalescentphas
sera
patient
infect
test
crossreact
sar
cov
immunofluoresc
neutral
test
patient
sera
six
eight
serial
serum
sampl
collect
first
month
ill
cohort
sar
patient
infect
amoy
garden
hong
kong
sar
eleven
patient
serum
sampl
collect
month
diseas
onset
sera
aliquot
store
use
patient
mean
age
year
rang
maletofemal
ratio
patient
present
high
fever
chill
rigor
myalgia
malais
cough
sore
throat
headach
fourteen
patient
diarrhea
mean
onset
day
two
patient
chronic
hepat
b
carrier
gener
patient
normal
hemoglobin
gliter
urea
mmollit
creatinin
mliter
alanin
aminotransferas
ulit
aspart
aminotransferas
ulit
white
cell
count
liter
level
howev
low
lymphocyt
count
liter
margin
low
platelet
count
liter
elev
creatinin
kinas
ulit
level
seven
patient
requir
admiss
intens
care
five
acut
respiratori
distress
syndrom
six
patient
fatal
outcom
acuteand
convalescentphas
sera
patient
recent
infect
patient
recent
infect
retriev
serum
bank
respiratori
pathogen
research
unit
baylor
colleg
medicin
kindli
provid
us
r
b
couch
sera
shown
exhibit
signific
increas
antibodi
titer
test
elisa
microneutr
test
r
b
couch
person
commun
prepar
covinfect
smear
sarscovinfect
vero
cell
cell
smear
use
studi
coronaviru
smear
prepar
accord
method
describ
previous
briefli
cell
evid
sarscov
antigen
express
cell
fix
chill
aceton
min
store
use
indirect
immunofluoresc
assay
sar
antibodi
detect
perform
use
indirect
immunofluoresc
sera
screen
dilut
infect
noninfect
control
cell
detect
igg
iga
iggam
antibodi
smear
incub
min
detect
igm
antibodi
sera
preabsorb
antihuman
igg
gull
sorb
min
room
temperatur
ad
onto
cell
follow
incub
h
cell
wash
twice
phosphatebuff
salin
min
time
antihuman
igg
iga
igm
inova
diagnost
san
diego
iggam
fluorescein
isothiocyan
conjug
focu
diagnost
inc
cypress
ca
ad
cell
incub
min
sera
posit
screen
dilut
titrat
serial
twofold
dilut
parallel
respect
acutephas
serum
specimen
patient
sequenti
serum
sampl
patient
assay
experi
weak
sar
cov
antibodyposit
serum
includ
posit
control
run
posit
result
score
fluoresc
intens
equal
higher
posit
control
antibodi
titer
taken
highest
serum
dilut
give
posit
result
epsteinbarr
viru
serolog
perform
accord
method
describ
previous
coronaviru
neutral
test
start
serum
dilut
serial
twofold
dilut
sera
prepar
microtit
plate
serum
dilut
ml
mix
ml
tissu
cultur
infecti
dose
sar
cov
incub
h
incub
ml
virusserum
mixtur
inocul
duplic
well
microtit
plate
preform
monolay
cell
sar
cov
incub
viru
backtitr
perform
assess
actual
viru
titer
use
experi
cytopath
effect
observ
use
invert
microscop
day
postinocul
neutral
titer
determin
highest
dilut
serum
complet
suppress
cytopath
effect
least
half
infect
well
experi
read
viru
backtitr
show
viru
dose
tissu
cultur
infecti
dose
expect
statist
analysi
antibodi
titer
transform
log
compar
use
mannwhitney
u
test
followup
sera
month
postonset
diseas
avail
patient
compar
highest
antibodi
titer
first
month
ill
igm
antibodi
level
fallen
least
fourfold
five
patient
undetect
three
geometr
mean
sar
cov
igm
titer
drop
month
postinfect
month
p
iga
antibodi
titer
decreas
least
fourfold
five
patient
remain
stabl
six
geometr
mean
iga
antibodi
titer
month
respect
p
contrast
one
patient
show
fourfold
greater
decreas
sar
cov
igg
antibodi
level
antibodi
level
stabl
seven
patient
continu
increas
three
patient
total
immunoglobulin
iggam
titer
decreas
one
patient
increas
two
patient
remain
stabl
eight
patient
neutral
antibodi
titer
decreas
two
patient
increas
two
patient
signific
chang
seven
patient
geometr
mean
antibodi
titer
month
month
postonset
ill
igg
respect
p
iggam
respect
p
neutral
titer
remain
unchang
p
sera
patient
sar
also
test
antibodi
use
indirect
immunofluoresc
test
virusinfect
cell
smear
rang
igg
titer
acutephas
serum
sampl
respect
seven
sar
patient
fourfold
greater
increas
igg
titer
tabl
fig
b
two
patient
least
fourfold
rise
titer
three
fourfold
greater
rise
antibodi
one
patient
show
decreas
antibodi
level
seven
show
signific
chang
antibodi
level
sera
four
sar
patient
rise
antibodi
respons
five
patient
crossreact
respons
virus
test
antibodi
respons
cell
five
patient
fourfold
greater
increas
antibodi
titer
three
also
show
rise
antibodi
titer
determin
whether
crossreact
respons
due
polyclon
activ
two
patient
signific
rise
antibodi
sar
cov
test
epsteinbarr
viru
viru
capsid
antigen
vca
igg
serv
antigen
unrel
control
neither
two
patient
signific
chang
epsteinbarr
viru
vca
igg
titer
pair
sera
patient
infect
acuteand
convalescentphas
sera
avail
patient
patient
infect
crossreact
antibodi
respons
virus
tabl
howev
sera
remain
neg
immunofluoresc
neutral
test
antibodi
sar
cov
data
shown
total
iggam
antibodi
antibodi
detect
earliest
mean
day
rang
day
patient
sar
subclassspecif
assay
igm
antibodi
earliest
antibodi
detect
mean
day
rang
day
although
igm
antibodi
titer
declin
significantli
first
month
infect
demonstr
sar
cov
igm
remain
detect
patient
least
month
previous
report
igm
antibodi
detect
elisa
becam
undetect
week
onset
ill
differ
result
may
relat
differ
sensit
method
use
serolog
test
contrast
neutral
antibodi
titer
iggam
igg
level
seem
stabl
first
month
postinfect
addit
signific
differ
kinet
appear
antibodi
respons
patient
surviv
die
sinc
serolog
remain
gold
standard
diagnosi
sar
import
explor
serolog
crossreact
sar
cov
human
coronavirus
show
sar
patient
fourfold
rise
titer
tabl
anoth
recent
studi
shown
evid
rise
antibodi
anim
immun
sar
cov
human
patient
sar
furthermor
subset
patient
test
also
rise
antibodi
titer
recent
discov
coronaviru
sinc
sar
patient
preexist
antibodi
sar
cov
infect
appear
stimul
crossreact
antibodi
respons
one
virus
could
due
crossreact
antigen
epitop
infect
result
polyclon
activ
antibodi
howev
patient
demonstr
crossreact
coronaviru
respons
signific
chang
antibodi
viru
unrel
famili
eg
epsteinbarr
viru
thu
presenc
crossreact
antigen
epitop
rather
polyclon
activ
antibodi
appear
explan
find
similarli
perhap
similar
reason
patient
one
three
patient
infect
induc
rise
antibodi
titer
viru
tabl
crossreact
human
coronavirus
note
complement
fixat
test
hand
patient
recent
infect
infect
without
prior
exposur
sar
cov
develop
antibodi
infect
viru
without
induc
crossreact
antibodi
respons
sar
cov
either
neutral
test
agreement
fact
neutral
antibodi
sar
cov
detect
uninfect
individu
lack
crossreact
respons
sar
cov
possibl
patient
prior
immunolog
memori
sar
cov
thu
less
opportun
crossreact
respons
given
evid
antigen
crossreact
coronavirus
remain
possibl
howev
may
inde
increas
antibodi
sar
cov
titer
patient
previous
sar
cov
infect
patient
subsequ
get
infect
remain
formal
demonstr
howev
awar
possibl
import
diagnost
point
view
crossreact
probabl
explain
posit
result
elisa
test
base
recombin
nucleoprotein
antigen
furthermor
hyperimmun
anim
antisera
group
human
summari
one
may
remain
confid
seroconvers
neutral
test
sar
cov
inde
conclus
evid
sar
cov
infect
howev
first
avail
serum
patient
alreadi
detect
antibodi
sar
cov
rise
antibodi
titer
sar
cov
may
necessarili
confirm
sar
cov
infect
remain
import
obtain
better
understand
crossreact
human
serolog
respons
coronavirus
purpos
laboratori
diagnosi
well
understand
pathogenesi
immun
